Design and syntheses of melanocortin subtype-4 receptor agonists: evolution of the pyridazinone archetype.
The discovery and optimization of a new class of non-peptidyl, pyridazinone derived melanocortin subtype-4 receptor agonists is disclosed.
Ujjainwalla
Feroze
F
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA. f_ujjainwalla@merck.com
Warner
Daniel
D
Walsh
Thomas F
TF
Wyvratt
Matthew J
MJ
Zhou
Changyou
C
Yang
Lihu
L
Kalyani
Rubana N
RN
MacNeil
Tanya
T
Van der Ploeg
Lex H T
LH
Rosenblum
Charles I
CI
Tang
Rui
R
Vongs
Aurawan
A
Weinberg
David H
DH
Goulet
Mark T
MT
D000818:Animals; D001665:Binding Sites; D006801:Humans; D007202:Indicators and Reagents; D007700:Kinetics; D051379:Mice; D008968:Molecular Conformation; D011724:Pyridazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D044105:Receptor, Melanocortin, Type 4 / Q000819:agonists*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D007202:Indicators and Reagents; D011724:Pyridazines; D044105:Receptor, Melanocortin, Type 4